Holocene Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Holocene Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,661	Closed	-$2.12M	–	919
2023 Q2	$2.12M	Buy	+20,661	New	+$2.18M	0.01%	534
2022 Q2	–	Sell	-638,444	Closed	-$67.2M	–	1073
2022 Q1	$67.2M	Sell	638,444 -267,236	-30%	-$26M	0.35%	94
2021 Q4	$97.6M	Buy	905,680 +524,819	+138%	+$57.3M	0.51%	64
2021 Q3	$41.7M	Buy	380,861 +350,116	+1,139%	+$36.3M	0.23%	135
2021 Q2	$2.88M	Buy	+30,745	New	+$2.83M	0.02%	476

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Holocene Advisors's HZNP Position: Q3 2023 in Review

Holocene Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 20,661 shares — an estimated $2.12M sold.

Holocene Advisors first reported a position in HZNP in Q2 2021 and held it in 5 quarters. The position peaked at $97.6M in Q4 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Holocene Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Holocene Advisors sold 20,661 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $2.12M.
Holocene Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 5 quarters.
Holocene Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $97.6M in Q4 2021.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Holocene Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.